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Abstract: Bioceramic scaffolds are appealing for alveolar bone regeneration, because they are 
emerging as promising alternatives to autogenous and heterogenous bone grafts. The aim of this 
systematic review is to answer to the focal question: in critical-sized bone defects in experimental 
animal models, does the use of a bioceramic scaffolds improve new bone formation, compared with 
leaving the empty defect without grafting materials or using autogenous bone or deproteinized 
bovine-derived bone substitutes? Electronic databases were searched using specific search terms. A 
hand search was also undertaken. Only randomized and controlled studies in the English language, 
published in peer-reviewed journals between 2013 and 2018, using critical-sized bone defect models 
in non-medically compromised animals, were considered. Risk of bias assessment was performed 
using the SYRCLE tool. A meta-analysis was planned to synthesize the evidence, if possible. 
Thirteen studies reporting on small animal models (six studies on rats and seven on rabbits) were 
included. The calvarial bone defect was the most common experimental site. The empty defect was 
used as the only control in all studies except one. In all studies the bioceramic materials 
demonstrated a trend for better outcomes compared to an empty control. Due to heterogeneity in 
protocols and outcomes among the included studies, no meta-analysis could be performed. 
Bioceramics can be considered promising grafting materials, though further evidence is needed. 
Keywords: animal study; bioceramic; bone grafting; critical-sized bone defect; scaffold 
 
1. Introduction 
One of the major challenges in dentistry, and in maxillofacial and orthopedic surgery, still 
remains to be the reconstruction of extensive bone defects [1,2]. The ideal bone substitute should be 
biocompatible, osteoconductive, and resorbable, and thereby replaced by newly formed bone, while 
maintaining adequate mechanical strength and structural support in the meantime, especially in 
load-bearing applications [3–5].  
Ceramic materials have been successfully used for the reconstruction of bone tissue defects [6,7]. 
The term bioceramics comprises a broad range of biocompatible inorganic non-metallic materials, 
characterized by a crystal structure, high melting point, electrical resistivity, and corrosion resistance 
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[8,9]. These features make them suitable for a variety of applications, including oral and maxillofacial 
surgery, periodontal treatments, and orthopedics [8]. However, one of the major drawbacks of 
ceramic scaffolds consists of their brittle behavior, which has restricted their use mainly to non-load-
bearing applications [10]. 
Among various bioceramics, calcium phosphates, such as hydroxyapatite (HA) and tricalcium 
phosphate (TCP), are commonly used bone grafting materials due to their resemblance to the bone 
mineral phase [10,11]. Besides calcium phosphate ceramics, more recently a new class of biomaterials, 
known as silicate bioceramics, have received significant attention for hard tissue regeneration [12–
15].  
The variety in chemical composition of bioceramics contributes to their adjustable mechanical 
features, bioactivity, and degradation rate. Another strategy to produce scaffolds with tailored 
mechanical properties and resorbability, based on application needs, consists of the development of 
composite materials, containing bioceramics and polymers in different ratios [16,17]. To improve the 
performances of bioceramic scaffolds, the incorporation of growth factors stimulating osteogenesis 
and angiogenesis has been described [18,19]. Moreover, bone scaffolds could act as stem cell carriers 
for accelerating bone repair [20]. 
In order to test bone substitute materials, preclinical in vivo studies in clinically relevant animal 
models are a fundamental step in translational research [21,22]. Various experimental approaches 
have been proposed, including the “critical-sized defect” (CSD) model [23,24]. An intrabony defect 
of critical dimensions is not expected, by definition, to heal spontaneously within the lifetime of the 
animal [25,26]. CSD models have been described for many kind of animal models. Among them, the 
use of rabbits and rats offers the advantages of easy handling and reduced experimental costs and 
timing. Despite the higher similarity to human bone (e.g., anatomy, biomechanics), the use of larger-
sized animals, such as dogs or pigs, is limited due to high experimental costs, more demanding 
management, the need for long follow-ups, and ethical concerns [21,27–29]. 
In order to assess new bone formation, several methods have been utilized, such as histological 
and histomorphometric analyses, gene expression analysis, and radiographic evaluations. Micro-CT 
analysis has been recently introduced as a complementary non-destructive approach to assess bone 
healing [30,31]. It does not require the sectioning of the sample, which might affect the three-
dimensional anisotropic information of bone architecture [30]. 
There are many reviews about different kinds of ceramic scaffolds for bone tissue regeneration, 
mainly focusing on biomaterial properties and production methods [6,7,10,12,14]. However, 
although preclinical in vivo studies in clinically relevant animal models represent a key aspect of 
translational research, there is no systematic review investigating the effects of bioceramic scaffolds 
on bone formation in CSD in experimental animal models, compared with the blood clot alone or 
with widely investigated materials, such as autogenous bone or deproteinized bovine-derived bone 
mineral (DBBM).  
Hence, the aim of this systematic review was to investigate the results of the application of 
bioceramic scaffolds in terms of bone regeneration in the treatment of CSDs in vivo in comparison 
with leaving the empty defect without grafting materials or with the use of autogenous bone or 
DBBM. The quality of the available studies was also assessed.  
2. Materials and Methods  
The protocol for this review was registered with the international prospective register of 
systematic reviews (PROSPERO) with registration n. CRD42019139963. 
2.1. Focal Question 
The present systematic review was conducted in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [32].  
The focused “PICO” (population, intervention, comparison, outcome) question addressed was 
the following: in bone defects in experimental animal models, does the use of a bioceramic scaffold 
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improve new bone formation, compared with leaving the empty defect without grafting materials or 
using autogenous bone or deproteinized bovine-derived bone substitutes? 
2.2. Eligibility Criteria 
2.2.1. Inclusion Criteria 
 Publication written in English. 
 Randomized or non-randomized controlled animal experimental studies with at least two study 
groups and at least 6 animals per group. 
 Use of experimental critical-sized bone defect (CSD) in non-medically compromised animals. 
2.2.2. Exclusion Criteria 
 In vitro studies, clinical studies, reviews, meta-analyses, conference proceedings, book chapters. 
 Animal studies reporting ectopic models (e.g., subcutaneous). 
 Absence of an empty defect and/or autogenous bone and/or deproteinized bovine-derived bone 
substitutes control group. 
 Treatment of periodontal defects. 
 Studies using scaffolds loaded with chemotherapeutic agents, anti-inflammatory drugs, 
antibiotics. 
 
Studies using scaffolds loaded with drugs/stem cells/substances affecting bone metabolism were 
not excluded. Table 1 summarizes the dimensions of the critical-sized bone defects in different animal 
models. 
Tooth extraction socket model was not considered a critical-sized bone defect model. 
Table 1. Definition of critical-sized bone defect (CSD). 
Animal Defect Site Dimension of CSD References 
Mouse 
Calvaria 4 mm diameter [33] 
Segmental long-
bone defect 
Radius: 4 mm 
Femur: 5 mm 
[34] 
Rat 
Calvaria Unilateral/central:8 mm diameter; bilateral: 5 mm diameter [23] 
Cylindric defect Femur: 2 mm in diameter and 3 mm in length  [35] 
Segmental long-
bone defect 
Radius: 1 cm diameter [36] 
Mandible 4 mm diameter [37] 
Rabbit 
Calvaria 
Four defects: 8 mm diameter; unilateral defect: 15 mm 
diameter; bilateral defect: 11 mm diameter  
[38] 
Segmental long-
bone defect 
Radius: defect > 1.4 cm involving periosteum [39] 
Cylindric defect 
Femur: 6mm in diameter and 5 mm in length; tibiae: 6 mm 
diameter 
[40] 
(femur) 
[41] (tibiae) 
Mandible 5 mm diameter [42] 
Pig 
Segmental long-
bone defect 
Femur: 7.6 cm; tibiae: 2 cm; radius: 2.5–3 cm; ulna: 2 cm [34,36] 
Sheep 
Calvaria  22 mm in diameter [43,44] 
Segmental long-
bone defect 
Femur: 2.5 cm; tibiae: 3–3.5 cm [34] 
Dog 
Calvaria 2 cm [45] 
Segmental long-
bone defect 
Femur: 2.1–7 cm; radius: 0.3–2.5cm; ulna: 2–2.5 cm [34] 
Segmental 
mandibular defect 
50 mm (in presence of periosteum); 15 mm (in absence of 
periosteum) 
[46] 
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2.3. Search Strategy, Screening Method, and Data Extraction 
The protocol for this review was registered with the international prospective register of 
systematic reviews (PROSPERO) with registration number CRD42019139963. The MEDLINE 
(PubMed) online library and the Web of Science (WoS) database were searched on 21th November 
2018. The search was limited to studies published between January 2013 and November 2018. The 
time-frame was selected considering the recent advancements in biomaterial production, such as the 
rise of additive manufacturing technologies. 
For the identification of studies to analyse for the present systematic review, detailed search 
strategies were developed for both databases, using a combination of the following keywords: 
“animal,” “bioceramic,” “bone,” “bone defect,” “bone regeneration,” “grafting,” and “in vivo.” 
Details of the search strategy are provided in the Supplementary Materials, Table S1. 
A 2-stage screening was carried out. The screening of the titles and of the abstracts was 
performed in duplicate and independently by two reviewers (G.B. and L.S.). Full texts of all eligible 
articles were obtained and reviewed independently by the same two reviewers (G.B. and L.S.). For 
each study, relevant data were extracted and recorded on a previously designed data collection form. 
The final inclusion was based on the aforementioned eligibility criteria. Reasons for exclusion were 
also entered. Cohen’s kappa statistic was calculated at both the stages, titles/abstracts and full texts, 
to measure the level of agreement between the two reviewers. In case of disagreement, when a 
consensus between the two reviewers was not reached after discussion, a third experienced reviewer 
(M.D.F.) was consulted.  
2.4. Outcome Measures 
2.4.1. Primary Outcomes 
New bone formation can be measured with different techniques (e.g., histomorphometric 
analysis, radiographic analysis like computed tomography (CT), micro-CT, standard radiographs); 
residual biomaterial. 
2.4.2. Secondary Outcomes 
Any complications and adverse events related to the biomaterials used. 
Scaffold production and characterization were also investigated. 
2.5. Quality Assessment and Risk of Bias Analysis 
The quality of the studies was assessed independently by two reviewers (S.P. and G.B.), based 
on the ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines [47]. The items 
considered were the following: ethical statement, experimental procedures, experimental animals, 
randomization, allocation concealment, sample size calculation, completeness of information, 
blinding of the evaluator, and financial conflict of interest. 
The risk-of bias of the studies was assessed by using the SYRCLE tool [48], evaluating 10 items. 
All items could be judged as yes/no/unclear. Studies were considered at high risk of bias if at least 
two items were judged as “no.” Studies were judged as low risk of bias if at least 7 items were judged 
as “yes” and no item was judged as “no.” In other cases the studies were considered at medium risk 
of bias. 
2.6. Data Synthesis and Statistical Analysis 
Due to the heterogeneity in study protocols, biomaterials used, methods for assessing the 
outcomes, outcome measures, and follow-up duration, no meta-analysis could be performed. Only 
qualitative data extracted from each study were synthesized in analytic tables. 
3. Results 
Materials 2020, 13, 1500 5 of 28 
 
3.1. Study Selection 
Only qualitative data extracted from each study were used in analytic tables. A total of 186 
articles were reviewed. After title/abstract screening, 78 articles were included as relevant for the 
purpose of the present systematic review. Following the final screening of full texts, 12 articles 
fulfilled the inclusion criteria and 66 papers were excluded. The reasons for exclusion are 
summarized in Table 2. The kappa values for inter-reviewer agreement were 0.91 and 0.90 for 
title/abstract selection and for full-text articles, respectively, thereby indicating almost perfect 
agreement. An additional article identified by handsearching was also included. Flow diagram of 
search results is shown in Figure 1: the number of articles for quantitative analysis was equal to zero; 
for this reason data were only qualitatively discussed. 
Table 2. Main reasons for exclusion after full-text screening. 
Main reason for Exclusion No. References 
Language 3 [49–51] 
In vitro study 2 [52,53] 
Ectopic bone formation model 4 [54–57] 
Use of compromised animals 4 [58–61] 
Absence of a control group 13 [62–74] 
Control group other than empty defect and/or autogenous bone and/or deproteinized 
bovine-derived bone 
20 [75–94] 
Unclear sample size 5 [95–99] 
Less than 6 animals per each test group 4 [100–103] 
Non-critical size bone defect 11 [104–114] 
 
Potentially relevant articles identified 
from electronic search 
(n = 241): 
WoS n = 150; PubMed n = 91 
Records after duplicates removed 
(n = 186) 
Articles excluded based on 
the title/abstract 
(n = 108) 
Full-text articles assessed for 
eligibility  
(n = 78) 
Full-text articles excluded, 
with reasons 
(n = 66) 
Studies included in qualitative 
synthesis 
(n = 13) 
Studies included in quantitative 
synthesis 
(n = 0) 
Additional articles 
identified through manual 
searching 
(n = 1) 
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Figure 1. Flowchart of the article selection procedure. 
3.2. Study Characteristics  
Only qualitative data extracted from each study were synthesized in analytic tables. In seven of 
the 13 included studies, New Zealand rabbits were used [16,115–120], while six studies were 
conducted in rats, of which three used the Sprague–Dawley strain [17,121,122], two the Wistar strain 
[123,124] and one the Lewis strain [125]. The calvarial critical-sized defect was the most used model 
for assessing new bone formation (Table 3). 
Two studies used bone marrow-derived mesenchymal stem cells (BMSCs) of different origins 
[17,115,120]. Interestingly, in none of those studies was the use of resorbable or non-resorbable 
membranes reported. Histological evaluation was the most frequent evaluation method (n = 13) to 
assess bone healing, followed by histomorphometric analysis (n = 6); radiographic evaluation (n = 4), 
micro-computed tomography analysis (n = 4); and other methods, less represented, including real-
time polymerase chain reaction (real-time PCR), Western blot, immunofluorescence, 
immunohistochemistry, scanning electron microscopy (SEM), and multi slice spiral computer 
tomography (MSCT). Follow-ups varied between two and 18 weeks. A single observation time was 
reported in two out of 13 studies [120,121], while the other studies had multiple observation times.  
Table 3. Distribution of defect types among the included studies. 
Animal Study Model Number of Publications  References 
Rabbit 
(n = 7) 
Calvarial defect  2 [116,117] 
Dome model (calvaria) 1 [119] 
Cylindrical femoral defect 1 [118] 
Segmental radial defect 1 [120] 
Mandibular square hole 2 [16,115] 
Rat 
(n = 6) 
Calvarial defect 5 [17,121–124] 
Cylindrical femoral defect 1 [125] 
As the chemical composition and processing technology are considered key factors for 
determining the properties of the scaffolds, they were analyzed and summarized in Table 4.  
A variety of production methods were reported, leading to the manufacturing of scaffolds with 
different compositions and morphologies, from 3D bone structures to particles of smaller dimensions, 
such as the microspheres employed in Xu et al. [117]. The definition of bone scaffold was not limited 
to 3D bone structures, but it was here used to describe a matrix allowing and stimulating cell 
attachment and proliferation on its surfaces. Interestingly, addictive manufacturing technologies, 
which present the main advantage of producing customized scaffolds tailored to the specific critical-
size bone defect [11], were utilized in two studies [116,122].  
As regards 3D bone structures, which could not only promote new bone formation, but could 
potentially be submitted to a mechanical load before the bone healing process is complete, no 
mechanical characterization was reported in all included studies, but one [116]. In Shao et al. [116], it 
was found that the dilute Mg doping and/or two-step sintering schedule was particularly beneficial 
for enhancing the mechanical strength of CaSi scaffolds, as reported in Table 4. 
Even though porosity and pore size are considered key parameters influencing the biological 
properties of biomaterials, as a porous structure provides an ideal environment for bone tissue 
ingrowth and repair, only in four studies was the porosity evaluated, with values ranging between 
53 and 93 vol.% (see Table 4) and pore size ranging between 100 and 500 µm. 
The chemical dissolution of the scaffold should be evaluated, as the mechanical integrity of the 
scaffold could be compromised during the healing time. Moreover, the release of some components 
might participate in human metabolism, thereby affecting bone formation. Only in two papers was 
the in vitro resorbability assessed (see Table 4) [17,118]. In addition, in Zong et al. [17] the scaffolds 
were implanted intramuscularly into rats to examine the in vivo degradation with results consistent 
with the in vitro findings. 
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Table 4. Bone scaffold production method and main properties. 
Ref. Biomaterial(s) Production Method Morphology 
Porosity 
(%) 
Density (g cm−3) 
Elastic 
Modulus (MPa) 
Compressive 
Strength (MPa) 
In vitro Resorbability 
[115] 
PEEK-BBC 
composite doped 
with VEGF 
HA + β-TCP bioceramic 
powder derived from 
extracted teeth, then 
impregnation in organic 
foam to prepare 
PEEK/BBC composite 
(calcined). 
Finally, immersion in 
polypeptide hydrogel 
containing VEGF. 
Intercon-
nected porous 
structure  
73.65 - - - - 
[16] 
PEEK-BBC 
composite 
HA + β-TCP bioceramic 
powder derived from 
extracted teeth, then 
impregnation in organic 
foam to prepare 
PEEK/BBC composite 
(calcined at 1250 °C). 
Intercon-
nected porous 
structure 
- - - - - 
[116] 
SLP CaSi 
Direct ink writing 
3D porous 
structure 
58.3 ± 1.9 - 
~55 (OSS) 
~60 (TSS) 
25 (OSS) 
25 (TSS) 
- 
SLP CaSi–Mg6 53.1 ± 1.4 - 
~135 (OSS) 
~164 (TSS) 
81 (OSS) 
103 (TSS) 
- 
DLP CaSi 59.2 ± 2.3 - 
~45 (OSS) 
~45 (TSS) 
18 (OSS) 
18 (TSS) 
- 
DLP CaSi–Mg6 53.5 ± 1.6 - 
~90 (OSS) 
~108 (TSS) 
~50 (OSS) 
~63 (TSS) 
- 
[117] 
Multi-layered 
CaP/CaSi 
microspheres 
Co-concentric capillary 
system 
Microspheres - - - - - 
[118] 
(a) 50CS/PAA (b) 
65CS/PAA 
In situ melting 
polymerization 
Granules - - - - 
WEIGHT LOSS: first 4 weeks: rapid 
degradation rate. Then, 50CS/PAA 
weight loss slow and subsequently 
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(CS/PAA 
composites 
containing 50 
and 65% (mass 
fraction) of CS) 
steady. 65CS/PAA weight loss 
continued to increase. 
Total weight loss (after 16 weeks in 
SBF) 41.5% for 50CS/PAA and 
56.2% for 65CS/PAA composite. 
SEM analysis: after 16 weeks of 
soaking, smoother surfaces. 
[119] 
HA 60% + TCP 
40% 
Commercially available Granules - - - - - 
[120] HA/TCP* Emulsion process 
3D porous 
structure 
- - - - - 
[17] nHA/PLA 
Porogen leaching 
technique (NaCl as 
porogen) 
3D porous 
structure 
~93 - - - 
WEIGHT LOSS: after 8 weeks in 
PBS: 
~10% nHAP/PLA  
50% PLGA  
[122] 
PLA/HA 
3D printing (mini-
deposition system) 
3D porous 
structure 
60.0 ± 1.5 - - - - 
β-TCP Animal-derived 
3D porous 
structure 
60 ± 10 - - - - 
[123] 
HA Chemical synthesis Powder - - - - - 
HaFS HA + animal-derived FS 
Mixture of 
HA powder 
and fibrin 
- - - - - 
[124] β-TCP-AE 
Base-catalysed sol–gel 
technique 
3D porous 
structure 
- 
0.15 ± 0.01 (no heat 
treatment), 0.52 ± 
0.02 (1000 °C) 
- - - 
[121] 
PLGA coated 
with Willemite 
(Zn2SiO4) 
Electrospun PLGA nano-
fibers coated with 
willemite 
Nanofibrous 
scaffold 
- - - - - 
[125] 
Merwinite 
Ca3Mg(SiO4)2 
Sol-gel Granules - - - - - 
HA Commercially available Powder - - - - - 
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* Calcium HA (65%) + TCP (35%); AE: mesoporous silica-based aerogel; β-TCP: β-tricalcium phosphate; BMSCs: bone marrow-derived mesenchymal stem cells; CaP: 
calcium phosphate; CaSi: calcium silicate; CaSi–Mg6: dilute Mg-doped CaSi; CS/PAA: calcium sulfate/poly(amino acid); DLP: double-layer printing; FS: fibrin sealant; HA: 
hydroxyapatite; nHA: nano-HA; OSS = one-step sintering; PEEK-BBC: polyether-ether-ketone biphasic bioceramic composite (HA and β-TCP); PLA: polylactic acid; PLGA: 
poly(lactic-co-glycolic acid); SLP: single-layer printing; TSS = two-step sintering; VEGF: vascular endothelial growth factor. 
For simplicity, the included studies are presented based on the animal model.  
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3.2.1. Studies in Rabbits—Main Features 
The characteristics and the main results of the studies in rabbits are summarized in Table 5. 
Notably, all the included studies reported uneventful healing outcomes and no relevant adverse 
reactions. Two studies reported on the use of polyether-ether-ketone/odontogenic biphasic 
bioceramic composites (PEEK-BBC) prepared via calcination for the treatment of mandibular bone 
defects [16,115]. Porous PEEK-BBC composites were found to promote bone healing in vivo, 
potentially via the upregulation of bone morphogenetic protein-2 (BMP-2), as suggested by the higher 
mRNA and protein expression levels of BMP-2 in the presence of PEEK-BBC composites, than in bone 
defects left empty [16]. Moreover, when vascular endothelial growth factor (VEGF) was encapsulated 
into PEEK-BBC composites, a relative upregulation of VEGF at 8 and 16 weeks of healing was 
observed compared to jaw defects left empty [115]. However, the specific effect of the exogenous 
VEGF, itself, encapsulated in the PEEK-BBC composites, could not be determined, due to the absence 
[115] of a control group treated with PEEK-BBC alone. 
In two studies the same calvaria bone defect model was used to assess the osteoconductive 
properties of different calcium phosphate and silica-based bioceramics [116,117]. In Shao et al., the in 
vivo behaviors of 3D-printed pure calcium silicate (CaSi) and dilute Mg-doped CaSi (CaSi–Mg6) 
scaffolds, characterized by different side-wall pore architectures depending on the deposition mode, 
were investigated [116]. Single-layer printing (SLP) scaffolds, featured by smaller layer thickness and 
interconnection size, exhibited a higher osteogenic capacity than double-layer printing (DLP) 
scaffolds in early phases (4 weeks). DLP scaffolds showed higher osteoconduction in later healing 
stages. Twelve months postoperatively, the highest percentage of new bone was observed in the 
group treated with CaSi scaffolds with double layer pore morphology (~26%), followed by DLP CaSi–
Mg6 (~23%). Even though DLP CaSi scaffolds promoted new bone formation to a greater extent, Mg 
doping considerably enhanced the mechanical properties of the scaffolds, which might be required 
in particular clinical situations. Details are provided in Figure 2. 
Dual-shell microspheres, composed of layers of slowly degraded β-TCP and rapidly degraded 
β-CaSi, displayed different bone regeneration patterns depending on the distribution of the materials 
within the dual-shell architectures [117]. Microspheres characterized by a core and an external layer 
of CaSi, separated by an intermediate β-TCP layer (CaSi@CaP@CaSi), showed superior performances 
in vivo, which might be due to the quick degradation of the external CaSi layer leading to an increased 
local silicon ion concentration. Interestingly, using micro-CT data from 12 weeks of healing, 
CaSi@CaP@CaSi microspheres [117] showed a bone volume/total defect volume ratio (BV/TV) of 
approximately 20% like SLP CaSi–Mg6 scaffolds [116], while the other 3D-printed scaffolds 
investigated in Shao et al. [116] exhibited higher values up to 27.5%.  
Calcium sulfate (CS) was utilized only in Li et al. [118], wherein it was incorporated into 
poly(amino acid) (PAA), to reduce the excessively rapid degradation rate of the former. Two CS/PAA 
composites containing 50% and 65% (mass fraction) of CS were produced via the in situ melting 
polymerization method and tested in a femoral bone defect model up to three months. Both the 
composites displayed good biocompatibility and similar amounts of newly formed bone. However, 
as in preliminary in vitro evaluations, the granules with higher CS content (65CS/PAA) exhibited a 
faster degradation rate. 
Resorbable biphasic calcium phosphate scaffolds, composed of HA and TCP, tested the 
remaining two included studies in rabbits [119,120]. In Ezirganlı al. [119], after three months of 
healing, the amount of newly formed bone was similar in DBBM and bicalcium phosphate groups. 
However, only DBBM group showed a significantly higher new bone formation compared to the 
empty group used as the control. Moreover, BMSCs of different origin (i.e., autologous, allogenic, 
ovine, and canine) seeded on biphasic calcium phosphate scaffolds were found to enhance new bone 
formation in radial segmental bone defects compared to defects filled with cell-free scaffolds and to 
untreated ones [120]. 
 
Materials 2020, 13, 1500 11 of 28 
 
Table 5. Summary of the characteristics and main results of studies in rabbits (n = 7). 
Ref. 
Sample 
Size (No. 
Animals) 
Defect Biomaterial(s) § 
Control 
(empty, 
DBBM, 
autogenou
s bone) § 
Other 
Materials/ 
Treatments § 
Stem 
Cells, 
Drugs, 
GFs 
Sacrifice 
(weeks) 
Assessment 
Method(s)  
Main Findings 
[115] 24 
Mandib-
ular square 
hole 12 × 
10 × 2 mm 
(length × 
width × 
depth) 
PEEK-BBC 
composite 
doped with 
VEGF 
(n = 6) 
Empty 
(n = 6) 
(a) no 
surgery 
(n = 6) 
(b) sham 
group—
surgery only, 
no defect (n 
= 6) 
VEGF 4, 8, 16 
Histological 
analysis; histo-
morphometric 
analysis; RT-
PCR; Western 
blot; immuno-
fluorescence 
Histological and histomorphometric analyses: 
the dimension of the defects in the empty group 
could be significantly lessened in the test group 
(p < 0.05). 
RT-PCR: 8 and 16 weeks: test group had a much 
higher mRNA level of VEGF than the empty 
group. 
Western blot: VEGF lower in the empty group 
compared with the test group (p < 0.05). 
Immunofluorescence: protein level of VEGF in 
the test group was much higher than that in the 
empty group. 
[16] 60 
Mandib-
ular square 
hole 12 × 
10 × 2 mm 
(length × 
width × 
depth) 
PEEK-BBC 
composite 
(n = 15) 
Empty 
(n = 15) 
(a) no 
treatment  
(n = 15) 
(b) only 
molar 
groove 
exposition (n 
= 15) 
- 4, 8, 16 
Histological 
analysis; RT-
qPCR; 
Western blot 
Histological analysis: low osteocytes in the 
empty group at each timepoint; presence of 
osteocytes at 4 weeks and increased number at 8 
and 16 weeks in the PEEK-BBC group. 
RT-qPCR: BMP-2 significantly higher in the 
PEEK group compared with the empty group at 
8 and 16 weeks. 
Western blot: 8 weeks: expression of BMP-2 
protein significantly upregulated by the PEEK-
BBC composites treatment compared with the 
empty group. 
[116] 24 
8 mm ϕ 
calvarial 
bone defect 
(4 for each 
animal) 
(a) SLP pure 
calcium silicate 
(CaSi);  
Empty 
(n = 4) 
- - 4, 8, 12 
Histological 
analysis; 
histomorphom
etric analysis; 
Histological and histomorphometric analyses: 
no inflammatory cells at 4 weeks in any group; 
at 12 weeks presence of mature bone with 
laminar structure both in CaSi and CaSi-Mg6 
group; DLP CaSi group showed more new bone 
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(b) SLP dilute 
Mg-doped CaSi 
(CaSi–Mg6);  
(c) DLP CaSi 
scaffold; (d) 
DLP CaSi–Mg6  
micro-CT 
analysis 
formation and a significant degradation of 
scaffold struts. 
Micro-CT: scaffold material decreased with time, 
while new bone formation increased overtime; 
the empty group revealed a very limited amount 
of bone regeneration; pure CaSi group showed 
limited material residual compared with the 
CaSi–Mg6 group, but more new bone tissue was 
intruded into the porous constructs of the pure 
CaSi scaffolds. 
[117] 15 
8 mm ϕ 
calvarial 
bone defect 
(4 for each 
animal) 
(a) CaP 
microspheres;  
multi-layered 
microspheres 
with layer order:  
(b) 
CaP@CaSi@CaP; 
(c) 
CaSi@CaP@CaSi 
Empty 
(n = 15) 
- - 6, 12, 18 
Histological 
analysis; 
micro-CT 
analysis 
Histological analysis: at 6 weeks no 
inflammation in all groups; at 18 weeks no 
difference between vessel concentration in all 
groups; at 6 weeks multinucleate cells were 
observed directly just onto the surface of the 
CaP@CaSi@CaP microspheres. 
Micro-CT: empty group not healed at 18 weeks; 
CaSi phase was preferentially biodegraded in 
both the external and internal layer; Tb.N 
increased with the BV/TV increasing; the new 
bone formation started from the periphery to the 
center of the defect. 
[118] 48 
Unilateral 
(desumed) 
femoral 
bone defect 
(6.5 mm in 
ϕ, 6 mm in 
depth) 
(a) 50CS/PAA 
(b) 65CS/PAA 
Empty 
(n = 16) 
- - 4, 12 
Histological 
analysis 
Histological analysis: small amount of newly 
formed bone at both 4 and 12 weeks in the 
empty group; 50CS/ PAA granules exhibited a 
slower degradation than 65CS/PAA granules. 
[119] 24 
Dome 
model (Ti 
barrier)—
bilateral 
calvaria (8 
mm ϕ Ti 
dome) 
HA 60% + TCP 
40% (4BoneTM) 
(a) Empty 
(n = 12) 
(b) Autoge-
nous blood 
(n = 12) 
- - 4, 13 
Histological 
analysis; histo-
morphometric 
analysis; 
micro-CT 
analysis 
Histological analysis: gap between the bone and 
the barrier in all groups; dense fibrous 
connective tissue between the titanium barrier 
and the bone in all groups; no sign of active 
bone formation in the first month, but active 
bone formation at 3 months; in the empty and 
autogenous blood groups loose connective 
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c) DBBM 
(Bio-Oss®) 
(n = 12) 
tissue at 1 month, that mineralized at 3 months; 
in Bio-Oss® and test groups no material 
resorption was found at 1 month, while 
osteoclastic activity was found at 3 months. 
Micro-CT and histomorphometric analyses: after 
1 month no statistically significant difference in 
bone volume augmentation among the groups; 
at the third month the increase in the amount of 
newly formed bone was statistically significant 
just between empty and Bio-Oss® groups. 
[120] 36 
Unilateral 
segmental 
radial 15-
mm bone 
defect 
a) HA/TCP* + 
autogenous 
rBMSC 
(n = 6) 
b) HA/TCP* + 
allogenic rBMSC 
(n = 6) 
c) HA/TCP* + 
ovine BMSCs 
(n = 6) 
d) HA/TCP* + 
canine BMSCs 
(n = 6) 
e) cell free 
HA/TCP* 
scaffold 
(n = 6) 
Empty 
(n = 6) 
- 
autolo-
gous, al-
logenic, 
ovine, 
canine 
BMSCs 
13 
Histologi-
cal/histopatho-
logical 
analysis;  
radiographic 
evaluation 
(multiple time 
points); SEM 
examinations 
Histopathological analysis: average bone 
formation (histological score): (a) > (b) > (d) > (c) 
> (e) > (empty), respectively: 3.0; 2.7; 2.2; 1.9; 
0.75; 0.2. 
Radiography: at 90 days bone formation mean 
values: (a) > (b) > (d) > (c) > (e) > (empty), 
respectively 12; 11.22; 11.20; 10.18; 06.05; 0.94. 
SEM: higher bone formation ad maturation, and 
higher scaffold degradation in group (a), 
followed by group (b); presence of new woven 
bone in the scaffold's pores in groups (c) and (d); 
poor bone formation and scaffold resorption in 
group (e); no bone formation at the entire length 
of the defect in the empty group, which was 
filled with fibrous tissue. 
§ (n=) represents the number of sites. *calcium HA (65%) + TCP(35%); BMSCs: bone marrow-derived mesenchymal stem cells; BV/TV: bone volume/total volume; CS/PAA: 
calcium sulfate/poly(amino acid); DLP: double-layer printing; GFs: growth Factors; HA: hydroxyapatite; PEEK-BBC: polyether-ether-ketone biphasic bioceramic composite 
(HA and β-TCP); RT-PCR: reverse transcription-quantitative polymerase chain reaction; SLP: single-layer printing; Tb.N: trabecular number; VEGF: vascular endothelial 
growth factor.  
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Figure 2. Osteogenesis of the ceramic scaffolds in vivo. (A) The cross-sectional images of implanted 
ceramic scaffolds of CaSi and CaSi–Mg6 with single layer pore morphology by microCT scanning 
after 4, 8, and 12 weeks, respectively. (B) The cross-sectional images of implanted ceramic scaffolds 
of CaSi and CaSi–Mg6 with double layer pore morphology by microCT scanning after 4, 8, and 12 
weeks, respectively. (C) Morphometric analysis of the volume of the newly formed bone (BV/TV) in 
the skull defect area at 4, 8, and 12 weeks with single layer pore morphology and double layer pore 
morphology, respectively. (*p < 0.05) [116]. 
3.2.2. Studies in Rats—Main Features 
The characteristics and the main findings of the studies in rats are provided in Table 6. 
In none of the included studies were adverse reactions to the implanted biomaterials reported. 
To evaluate the osteogenic potential of the bioceramics in rats, calvarial critical-sized defects were 
used in all studies but one [125].  
Porous composite scaffolds, composed of HA and polylactic acid (PLA) and produced with 
different techniques, were tested in two studies [17,122]. In Zong et al. [17], nano-HA/PLA scaffolds 
fabricated by a porogen-leaching technique and loaded with BMSCs were able to induce bone 
formation in vivo. Nevertheless, higher new bone formation was detected in defects grafted with 
poly(lactic-co-glycolic acid) (PLGA) scaffolds seeded with BMSCs, with average new bone formation 
of about 50% after 16 weeks of healing, against the approximately 30% found in the group treated 
with nano-HA/PLA loaded with BMSCs. It was inferred by the authors that the lower degradation of 
nano-HA/PLA scaffold compared to PLGA matrix could be responsible for its inferior bone-repairing 
effects. Interestingly, no bone regeneration was observed in defects filled with nano-HA/PLA 
scaffolds alone.  
In contrast with these findings, in Zhang et al. [122] highly resorbable three-dimensional (3D) 
printed PLA/HA scaffolds showed good bone repairing capacity, as confirmed by histological 
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examination (Figure 3). As revealed by micro-CT data, both at four and eight weeks after surgery the 
highest amount of bone volume per total volume (BV/TV) was found in the defects filled with β-TCP 
ceramic scaffolds, with values around 50%, followed by PLA/HA scaffolds, and then, by partially 
demineralized bone matrix (DBM).  
 
Figure 3. Hematoxylin and eosin images of implanted and control group after four and eight weeks. 
(A) Histological images of implanted (1) PLA/HA, (2) β-TCP, and (3) DBM scaffolds, and (4) the 
control group four weeks after implantation. (B) Histological images of (1) implanted PLA/HA, (2) β-
TCP, and (3) DBM scaffolds, and (4) the control group eight weeks after implantation. Scale bars 10 
µm [122]. 
Combining HA with a fibrin sealant (FS) derived from snake venom exerted a beneficial effect 
on bone healing, compared to HA or fibrin sealant alone, as confirmed by histomorphometric 
analysis [123]. Six weeks postoperatively, the highest relative volume of new bone was recorded in 
HA/FS samples (53.66 ± 0.57%), whereas in empty defects, HA and FS groups lower values were 
registered (i.e., 10.66 ± 0.57%, 20.66 ± 1.15%, and 29.66 ± 1.52%, respectively). 
In two papers the osteoconductive capacity of the bioceramic scaffolds was evaluated using 8 
mm cylindrical bone defects in a rat’s calvaria [114,124]. Despite the same model being used in these 
studies, no direct comparison could be drawn due to the different timepoints selected by the authors.  
Silica aerogel-based β-TCP composite was demonstrated [124] to better support new bone 
formation compared to the mesoporous silica aerogel alone. Interestingly, three months after 
implantation, most of the aerogel-based β-TCP composite was resorbed and signs of intense bone 
remodeling and ossification were confirmed by histological observations and immunohistochemistry 
for Ki-67. At this stage, bone defects filled with silica aerogel alone exhibited bone ossification to a 
lower extent, whereas only a minimal ossification in the periphery of the defects was detected in the 
untreated control group.  
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Table 6. Summary of the characteristics and main results of studies in rats (n = 6). 
Ref. 
Sample 
size (No. 
animals) 
Defect 
Biomateri-
al(s) § 
Control 
(empty, 
DBBM, 
autogenou
s bone) § 
Other 
material
s/treatm
ents § 
Stem 
cells, 
drugs, 
GFs 
Sacrifice 
(weeks) 
Assessment 
method(s) 
Main findings 
[17] 24 
5 mm ϕ 
bilateral 
calvarial 
bone defect 
(a) 
nHA/PLA + 
hBMSCs  
(n = 12) 
(b) 
nHA/PLA  
(n = 6) 
Empty 
(n = 12) 
(a) 
PLGA + 
hBMSCs 
(n = 12) 
(b) 
PLGA 
(n = 6) 
hBMSCs 8, 16 
Histological 
analysis; 
histo-
morphometric 
analysis; 
immunohisto-
chemistry; 
radiography; 
(weight loss 
profile of the 
scaffold after 
in vivo 
implantation 
intramuscu-
larly) 
Histological analysis: 8 weeks: minimal amount of bone-like tissue in defect 
with nHA/PLA + hBMSCs while no bone regeneration in the other groups; 16 
weeks: newly formed bone in defects with PLGA + hBMSCs was larger than 
that in defects with nHA/PLA + hBMSCs, loose connective tissue in defects 
filled with scaffolds alone without cells or left unfilled; no obvious residual 
scaffold material in all defects both at 8 and 16 weeks. 
Histomorphometric analysis: new bone formation percentage in PLGA + 
hBMSCs and nHA/PLA + hBMSCs groups was higher than in the others (P < 
0.05).  
Radiography: 8 weeks: no significant bone regeneration in any groups; 16 
weeks: no sign of bone regeneration found in defects filled with scaffolds 
alone without cells. 
Immunohistochemical analysis: both at 8 and 16 weeks no positive staining of 
osteocalcin in empty defects and defects filled with scaffolds alone, while 
positive staining in defects filled with scaffolds seeded with cells. 
[122] 32 
5 mm ϕ 
unilateral 
calvarial 
bone defect 
(a) PLA 
(85% wt) + 
HA (15% 
wt) 
(n = 8) 
(b) β-TCP (n 
= 8) 
Empty 
(n = 8) 
DBM 
(n = 8) 
- 4, 8 
Histological 
analysis; 
immunohistoc
hemical 
analysis; 
micro-CT 
analysis; 
hematological 
analysis 
Histological analysis: new bone around and in contact with the biomaterials; 
blank group filled with compressed fibrous-connective tissue. 
Immunohistochemistry: osteocalcin and type I collagen expression: PLA + 
HA> β-TCP > DBM; new bone %: β-TCP> PLA + HA > DBM> blank group 
Micro-CT analysis: new bone areas in empty control group were less than in 
the other implanted groups at both timepoints; the results of total degradation 
rates showed no significant difference between 3DP PLA/HA scaffolds and 
DBM scaffolds at eight weeks and β-TCP had the lowest degradation rates in 
all groups; 
Hematological analysis: leukocyte cell counts and red blood cell levels were 
similar in all implanted groups at the four time points (12 days, and 4, 6 and 8 
weeks after the surgery). 
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[123] 40 
5 mm ϕ 
monolateral 
calvarial 
bone defect 
(a) HA 
particles 8 
mg 
(n = 10) 
(b) HA 8 mg 
+ FS 8 mL 
(n = 10) 
Empty 
(n = 10) 
FS 8mL 
(n = 10) 
- 2, 6 
Histological 
analysis; 
histomorpho
metric 
analysis; 
radiography 
Histological and histomorphometric analyses: 2 weeks: new bone formation 
from the periphery to the center of the defect; higher bone formation in the 
HA + FS group. 6 weeks: presence of mature newly formed bone in treated 
group; higher bone formation and lower connective tissue amount in the HA + 
FS group than in the HA group. 
[124] 19 
8 mm ϕ 
unique 
calvarial 
bone defect 
β-TCP-AE 
(n = 6) 
Empty 
(n = 7) 
AE 
(n = 6) 
- 4, 13 
Histological 
analysis; 
immunohistoc
hemistry 
Histological and immunohistochemical analyses: 4 weeks: both test groups 
showed intense inflammation-associated fibrosis; control group showed 
fibrous-inflammatory tissue with moderate degree of calcification; in β-TCP-
AE group granulation tissue and presence of polymorphonuclear leukocytes, 
macrophages and fibroblasts. 13 weeks: β-TCP-AE almost totally degraded, 
and significantly less inflammatory cells than at 4 weeks, with presence of 
solid and compact bone islands; the empty control group exhibited a minimal 
ossification along the internal rim of the bone defect; only the β-TCP-AE 
group exhibited intense ossification. 
[121] 30 
8 mm ϕ 
unique 
calvarial 
bone defect 
(not central) 
PLGA 
coated with 
Willemite 
(n = 10) 
Empty 
(n = 10)  
PLGA 
(n = 10) 
- 8 
Histological 
analysis; 
histomorpho
metric 
analysis; 
radiography; 
MSCT 
Histological and histomorphometric analyses: highest bone reconstruction in 
animals treated with willemite-PLGA; enhanced collagen deposition 
willemite-PLGA group than in PLGA group. 
MSCT and radiography: no evidence of neo-tissue regeneration in the 
untreated animals; rats receiving willemite-PLGA had the highest bone 
regeneration; neo-tissue formation started from the periphery of the defect site 
toward the center. 
[125] 24 
bilateral 
femoral 
bone defects 
(3 mm in ϕ, 
2 mm in 
depth) 
(a)granules 
of 
merwinite 
(n = 16) 
(b) HA 
(n = 16) 
Empty 
(n = 16) 
- - 2, 8 
Histological 
analysis 
Histological analysis: 2 weeks: no bone formation in the HA group, but 
presence of loose and fibrous connective tissue; connective tissue and small 
bone islands in merwinite group; 8 weeks: new bone until the center of the 
merwinite scaffold; higher bone formation and scaffold degradation in the 
merwinite group than in HA one; presence of irregular trabecular bone and 
beginning of Harvesian system formation in some areas; the control untreated 
group presented connective tissue both at 2 and 8 weeks and a slower healing. 
§ (n=) represents the number of sites. AE: mesoporous silica-based aerogel; β-TCP: β-tricalcium phosphate; DBM: partially demineralized bone matrix; HA: hydroxyapatite; 
hBMSCs: human bone marrow-derived mesenchymal stem cells; FS: fibrin sealant; MSCT: multislice spiral computed tomography; nHA: nano-HA; PLA: polylactic acid; 
PLGA: poly(lactic-co-glycolic acid). 
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PLGA electrospun nanofibers coated with a bioactive silica-based ceramic containing zinc and 
willemite (Zn2SiO4) were proved to be promising candidates for bone tissue engineering applications 
[121]. After 8 weeks of healing, in the defects treated with willemite-coated PLGA scaffolds, the area 
of reconstructed bone tissue, resulting from quantitative analysis of histologic and multislice spiral-
computed tomography data, was found to be approximately 70%, twice the amount of bone detected 
in the rats receiving PLGA scaffolds with no bioceramic coating.  
Another silica-based ceramic, merwinite [Ca3Mg(SiO4)2], was found to enhance new bone 
formation in rat femoral defect model to a greater extent than HA ceramics and leaving the defects 
unfilled [120]. It is likely that the higher in vivo material degradation of merwinite granules compared 
to HA ones induced a wider and faster osteogenesis, hence confirming the superior bioactive 
properties of this material.  
3.3. Study Quality and Risk of Bias Assessment 
A study quality assessment according to the ARRIVE guidelines is shown in Table 7. Scoring 
criteria are provided in Table S2. 
All the studies reported data on ethical statements and provided detailed information about the 
experimental procedures and outcome evaluation (items 1, 2, 7, respectively). All the studies, except 
one, gave adequate information about experimental animals (item 3), while the majority of studies 
lacked complete information regarding allocation concealment (item 5) and blinding of the evaluator 
(item 8). Only in six studies (46.1%) were animals or defects randomly allocated to different treatment 
groups (item 4) and no study provided information on the sample size calculation (item 6). Finally, 
regarding financial conflict of interest and possible role of the funders, approximately half of the 
studies (53.8%) provided clearly adequate information, whereas in the remaining six studies, the 
information was unclear/possibly adequate. 
Table 7. Study quality assessment. 
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[115] 2 2 0 2 1 0 2 1 2 
[16] 2 2 2 0 1 0 2 1 2 
[116] 2 2 2 2 2 0 2 1 1 
[117] 2 2 2 2 1 0 2 1 2 
[118] 2 2 2 0 1 0 2 1 1 
[119] 2 2 2 1 1 0 2 1 2 
[120] 2 2 2 0 0 0 2 1 2 
[17] 2 2 2 2 1 0 2 1 1 
[122] 2 2 2 2 1 0 2 1 2 
[123] 2 2 2 1 1 0 2 1 1 
[124] 2 2 2 1 1 0 2 1 2 
[121] 2 2 2 2 1 0 2 1 1 
[125] 2 2 2 0 1 0 2 1 1 
Risk of Bias Assessment of the selected studies according to the SYRCLE tool is provided in 
Table 8.  
 
 
Table 8. Risk of bias assessment. 
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[115] Yes No Unclear Yes Yes Yes No Yes Unclear Yes 
[16] Yes Yes Unclear Yes Yes Yes No Yes Unclear Yes 
[116] Yes Yes Yes Yes No Yes Unclear Yes Unclear Yes 
[117] Yes Yes Unclear No No Yes Unclear Yes Unclear Yes 
[118] Yes Yes Unclear No No Yes Unclear Yes Unclear Yes 
[119] Yes Yes Unclear Yes No Yes Unclear Yes Unclear Yes 
[120] Yes Yes Unclear Yes No Yes Yes Yes Unclear Yes 
[17] Yes Yes Unclear No No Yes No Yes Unclear Yes 
[122] Yes Yes Unclear Yes No Yes No Yes Unclear Yes 
[123] Yes Yes Unclear No No Yes No Yes Unclear Yes 
[124] Yes Yes Unclear No No No No Yes Unclear Yes 
[121] Yes Yes Unclear No No No No Yes Unclear Yes 
[125] Yes Yes Unclear Yes No Yes No Yes Unclear Yes 
4. Discussion 
The aim of this systematic review was to investigate the role of bioceramic scaffolds in 
regenerating critical-sized bone defects in experimental animal models, compared with leaving the 
empty defect without grafting materials or filling the defects with autogenous bone or deproteinized 
bovine-derived bone substitutes. Overall, the results showed that bioceramic scaffolds better 
supported new bone formation, compared to untreated empty defects. In general, there was only a 
limited spontaneous bone regeneration at the site of defects substituted with no material. In none of 
the included studies were autogenous bone grafts used as controls, whereas, when DBBM was 
considered, a similar amount of new bone formation was observed in DBBM and bioceramic groups 
[119]. 
The most frequent reason for exclusion was the absence of a control group overall, along with 
the absence of a control group consisting of leaving the defect without any biomaterials and/or filling 
it with autogenous bone graft and/or DBBM. Eleven papers were not included due to the sizes of the 
defects, which were not considered of critical dimensions.  
Numerous bioceramic and composite materials for bone regeneration were developed and 
tested in vivo in CSD. However, the considerable heterogeneity among the selected studies, in terms 
of scaffold composition, size, and type of the defect and observation time, did not allow cross-study 
comparisons. Indeed, due to the lack of standardization of these variables across the studies together 
with the few quantitative data reported, a meta-analysis could not be performed and the 
generalizability was limited.  
No extensive physico-chemical and mechanical characterization was reported in most of the 
studies. Regarding the fabrication of the scaffolds, resumed in Table 4, many production technologies 
were applied, leading to the manufacturing of bioceramic powders within a polymeric matrix or 3D 
scaffolds. In two studies [119,125], commercially available biomaterials were used. However, for the 
other produced materials, only lab-scaled processes were investigated.  
Although studies in dogs, minipigs, sheep, and non-human primates, could provide a better 
insight into new bone formation and scaffold effectiveness thanks to the closer resemblance to the 
human bone, only studies employing rat and rabbit models were found to satisfy eligibility criteria, 
and were, therefore, included in the present systematic review [21,27–29,126]. Even though after the 
first step of screening, studies in dogs, sheep, and pigs were included, the full-text analysis revealed 
that most of these studies did not meet the selection criteria due to a reduced sample size (n < 6 
animals per group) or the non-critical dimensions of the bone defects [94,100,102,103,106]. Among 
the papers included, the most frequently used CSD model was the CSD in rat calvaria, which is one 
of the most commonly used animal models for evaluating bone healing [23,127]. 
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Despite the high heterogeneity among the studies, bioceramic scaffolds generally showed a 
remarkable osteoconductive effect. However, it was not possible to determine which bioceramic 
performed better than the others and in regard to which kind of CSD. 
Scaffold architecture is considered a fundamental aspect in tissue engineering. A bone scaffold 
should present an interconnected porous structure mimicking that of natural bone, thus facilitating 
cell ingrowth, proliferation, and differentiation, as well as the diffusion of nutrient and the removal 
of waste products [128]. In the meantime, the scaffold should possess adequate mechanical 
properties, which are particularly required for load-bearing applications [129]. It has to be stressed 
that, although these aspects are of primary importance, in most of the articles no comprehensive 
characterization of the scaffolds was provided and compressive strength values were reported in only 
one work [116]. 
An ideal scaffold should also possess an adequate degradation rate, matching the osteogenesis 
rate occurring in the replaced bone [118,130]. One of the strategies to tailor the biodegradability of a 
scaffold consists of the development of composite materials, composed of biodegradable polymers 
and bioceramic particles, added as fillers or as coatings. Therefore, in composites the osteoconductive 
properties of the bioceramics are combined with the easy processing and faster resorbability of the 
polymers [17,118,131,132]. Interestingly, in two articles the in vitro degradation of the scaffolds was 
evaluated [17,118]. In Li et al. [118], two calcium sulfate/poly(amino acid) (CS/PAA) scaffolds, 
characterized by different CS content, exhibited weight losses of 41.5% and 56.2% after soaking in 
simulated body fluid (SBF) for 16 weeks, thereby indicating that the relative amount of CS in the 
composite affected the degradability of the material. In contrast, in Zong et al. [17], after 8 weeks in 
phosphate buffered saline (PBS), the weight loss of the composite scaffold (i.e., nHAP/PLA) was 
nearly 10% of its initial weight, while the weight loss rate of PLGA scaffold was much higher, with 
values around 50%. The authors assumed that the in vivo performances of nHAP/PLA scaffolds in 
terms of new bone formation were lower than expected due to the low degradation of the scaffold, 
hampering the regeneration process.  
With regard to the incorporation of bioactive molecules for localized and controlled delivery 
[18,19], in one study [115] VEGF, a potent angiogenic factor, was successfully encapsulated within a 
PEEK/biphasic bioceramic composite scaffold and found to facilitate the vascular remodeling in vivo.  
Furthermore, bone scaffolds were used as stem cell carriers for accelerating and promoting bone 
repair in two articles [17,120]. In particular, BMSCs, pluripotent mesenchymal stem cells with the 
proven ability to differentiate into different cell lineages, including osteoblasts [133–135], were used 
in both studies. The combination of BMSCs and HA/TCP scaffolds for the treatment of rabbit 
segmental radial bone defects showed increased quantity of newly formed compared to the 
bioceramic scaffold alone [120]. Moreover, a higher bone-repairing effect was exhibited by nano 
HA/PLA scaffolds seeded with BMSCs than by the composite scaffolds alone in rat calvarial CSD 
model [17]. These findings are in agreement with what has been reported in other studies, in which 
bone regeneration was aided by the addition of BMSCs seeded onto the scaffolds before implantation 
[136,137]. 
5. Conclusions 
In conclusion, several bioceramic scaffolds were demonstrated to be osteoconductive in a variety 
of animal models, showing better results than leaving the bone defects with no grafting material. It 
was not possible to compare the investigated scaffolds with autogenous bone, and only in one study 
was DBBM evaluated, showing similar behavior in vivo. The results also indicated that composite 
materials, comprising bioceramic particles and polymers, could be promising candidates as bone 
substitutes. Bioceramic scaffolds should therefore be applied in the repair of bone defects on a regular 
basis, in order to promote bone tissue healing. Regarding the use of stem cells or growth factors, there 
is still scarce, though promising evidence that the addition of mesenchymal stem cells or VEGF to the 
scaffolds further enhances bone regeneration in preclinical in vivo studies. 
However, due to the high variability among the studies with regard to the compositions of the 
biomaterials, the production methods, the type and dimensions of the bone defects used, and the 
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follow-up duration, no conclusive statements about the clinical effectiveness of bioceramic scaffolds 
for bone regeneration can be made. In the future, in vivo animal models should be designed following 
standardized parameters (i.e., adoption of critical-sized defects, empty control group, and 
quantitative measurements for bone formation), in order to allow the comparison of findings, thereby 
favoring the advancement of knowledge in this fast-growing area of research. Moreover, further 
studies are needed in order to determine the optimal evaluation times for each CSD in different 
animal models. 
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